

# Global Markets for Neglected Tropical Disease Treatments

<https://marketpublishers.com/r/GA1BDA5B0A0EN.html>

Date: June 2017

Pages: 161

Price: US\$ 2,750.00 (Single User License)

ID: GA1BDA5B0A0EN

## Abstracts

The global market for neglected tropical diseases should reach \$2.6 billion by 2021 from \$1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.

The market for malaria treatments is expected to grow from \$513.5 million in 2016 to \$757.9 million in 2021 at a CAGR of 8.1% for the period 2016-2021.

The dengue (vaccine) segment of the neglected tropical diseases market is expected to grow from \$299.4 million in 2016 to \$1.3 billion in 2021 at a CAGR of 34.8% for the period 2016-2021.

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing this Study  
Scope of Report  
Information Sources  
Methodology  
Geographic Breakdown  
Analyst's Credentials  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 4 MARKET OVERVIEW**

### **CHAPTER 5 MARKET INFLUENCING FACTORS**

### **CHAPTER 6 RESEARCH AND DEVELOPMENT**

### **CHAPTER 7 PATENT REVIEW**

### **CHAPTER 8 COMPANY PROFILES**

Total Addressable Market  
Malaria  
Malaria Market Share by Geography  
Leishmaniasis  
Leishmaniasis Market Share by Geography  
Schistosomiasis  
Schistosomiasis Market Share by Geography  
Lymphatic Filariasis  
Lymphatic Filariasis Market Share by Geography  
Chagas Disease  
Chagas Disease Market Share by Geography  
African Trypanosomiasis  
Dengue  
Dengue Market Share by Geography

Ebola

Zika

Zika Market Share by Geography

Donations by Pharmaceutical Companies: Access to Medicines

Market Drivers

Market Deterrents

Malaria

Leishmaniasis

Lymphatic Filariasis

Chagas Disease

African Trypanosomiasis

Dengue

Ebola

Zika

Malaria

Leishmaniasis

Schistosomiasis

Lymphatic Filariasis

Chagas Disease

African Trypanosomiasis

Dengue

Ebola

Zika

Unmet Needs

Malaria

Leishmaniasis

Schistosomiasis

Lymphatic Filariasis

Chagas Disease

African Trypanosomiasis

Dengue

Ebola

Zika

Malaria

Clinical Trials in Malaria

Leishmaniasis

Clinical Trials in Leishmaniasis

Schistosomiasis

Clinical Trials in Schistosomiasis

Lymphatic Filariasis  
Clinical Trials in Lymphatic Filariasis  
Chagas Disease  
African Trypanosomiasis  
Dengue  
Ebola  
Zika  
Clinical Trials in Chagas Disease  
Clinical Trials in African Trypanosomiasis  
Clinical Trials in Dengue  
Clinical Trials in Ebola  
Clinical Trials in Zika  
Malaria  
Patent Review by Assignee  
Patent Review by Year  
Patent Review by Country  
Patent Review by Type  
Leishmaniasis  
Patent Review by Assignee  
Patent Review by Year  
Patent Review by Country  
Patent Review by Type  
Schistosomiasis  
Patent Review by Assignee  
Patent Review by Year  
Patent Review by Country  
Patent Review by Type  
Lymphatic Filariasis  
Patent Review by Assignee  
Patent Review by Year  
Patent Review by Country  
Patent Review by Type  
Chagas Disease  
Patent Review by Assignee  
Patent Review by Year  
Patent Review by Country  
Patent Review by Type  
African Trypanosomiasis  
Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Dengue

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Ebola

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

Zika

Patent Review by Assignee

Patent Review by Year

Patent Review by Country

Patent Review by Type

ANACOR PHARMACEUTICALS (NOW PFIZER)

BAYER

BUTANTAN

(DNDI) DRUGS FOR NEGLECTED DISEASES INITIATIVE

EISAI

GILEAD SCIENCES

GLAXOSMITHKLINE

MERCK

(MMV) MEDICINES FOR MALARIA VENTURE

NOVARTIS

THE PATH MALARIA VACCINE INITIATIVE

SABIN VACCINE INSTITUTE

SANOFI-AVENTIS/SANOFI PASTEUR

TAKEDA

## **CHAPTER 9 APPENDIX: ABBREVIATIONS**

Research Portfolio and Alliances

Access to Medicines

Research Portfolio and Alliances

Research Portfolio and Alliances

Research Portfolio  
Research Portfolio and Alliances  
Access to Medicines  
Research Portfolio and Alliances  
Access to Medicines  
Research Portfolio and Alliances  
Research Portfolio and Alliances  
Access to Medicines  
Access to Medicines  
Research Portfolio and Alliances  
Research Portfolio and Alliances  
Access to Medicines  
Research Portfolio and Alliances  
Research Portfolio and Alliances  
Research Portfolio and Alliances  
Access to Medicines:  
Research Portfolio and Alliances  
Research Portfolio and Alliances

## **CHAPTER 3 DISEASE OVERVIEW**

Malaria  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
Leishmaniasis  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
Schistosomiasis  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
Lymphatic Filariasis  
Incidence and Geographical Distribution  
Etiology and Symptoms

Socioeconomic Burden  
Current Method of Treatment  
Chagas Disease  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
African Trypanosomiasis  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
Dengue  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
Ebola  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment  
Zika  
Incidence and Geographical Distribution  
Etiology and Symptoms  
Socioeconomic Burden  
Current Method of Treatment

## List Of Tables

### LIST OF TABLES

Summary Table Global Market for Neglected Tropical Diseases, by Indication, Through 2021

Table 1 Key Trends in Neglected Tropical Diseases

Table 2 Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015

Table 3 Suspected Malaria Cases, 2010-2015

Table 4 Confirmed Malaria Cases, 2010-2015

Table 5 Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014

Table 6 WHO Guidelines for Treatment of Malaria

Table 7 Number of Cases of CL in Select High Burden Countries, 2010-2014

Table 8 Number of Cases of VL in Select High Burden Countries, 2010-2014

Table 9 Incidence of CL and VL in High Burden Countries, 2014

Table 10 Global Disease Burden of Leishmaniasis, 2015

Table 11 WHO Guidelines for Treatment of Leishmaniasis

Table 12 Number of People Treated Globally, 2010-2014

Table 13 Global Disease Burden of Schistosomiasis, 2015

Table 14 Global Disease Burden of Lymphatic Filariasis, 2015

Table 15 Prevalence and Incidence (Number) of Chagas Disease, 2015

Table 16 Global Disease Burden of Chagas Disease, 2015

Table 17 Prevalence and Incidence (Number) of Chagas Disease, 2015

Table 18 Global Disease Burden of African Trypanosomiasis, 2015

Table 19 Prevalence and Incidence (Number) of Dengue Cases, 2015

Table 20 Reported Cases and Deaths in Ebola Outbreaks, 2007-2016

Table 21 Zika Burden, 2015-2016

Table 22 Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021

Table 23 Global Addressable Market for Malaria, by Region, Through 2021

Table 24 Global Addressable Market for Leishmaniasis, by Region, Through 2021

Table 25 Global Addressable Market for Schistosomiasis, by Region, Through 2021

Table 26 Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021

Table 27 Global Addressable Market for Chagas Disease, by Geography, Through 2021

Table 28 Global Addressable Market for Dengue, by Region, Through 2021

Table 29 Global Addressable Market for Zika, by Region, Through 2021

Table 30 Drug Donation Commitments, by WHO

Table 31 Malaria Development Pipeline and Recent Launches

Table 32 Leishmaniasis Development Pipeline and Recent Launches



Table 33 Schistosomiasis Development Pipeline and Recent Launches

Table 34 Lymphatic Filariasis Development Pipeline and Recent Launches

Table 35 Chagas Disease Development Pipeline and Recent Launches

Table 36 African Trypanosomiasis Development Pipeline and Recent Launches

Table 37 Dengue Development Pipeline and Recent Launches

Table 38 Ebola Development Pipeline and Recent Launches

Table 39 Zika Development Pipeline and Recent Launches

Table 40 Number of Patent Applications, Malaria, by Assignee

Table 41 Number of Patent Applications, Malaria, by Year, 2010-2015

Table 42 Number of Patent Applications, Malaria, by Country

Table 43 Number of Patent Applications, Malaria, by Type

Table 44 Number of Patent Applications, Leishmaniasis, by Assignee

Table 45 Number of Patent Applications, Leishmaniasis, by Year, 2010-2015

Table 46 Number of Patent Applications, Leishmaniasis, by Country

Table 47 Number of Patent Applications, Leishmaniasis, by Type

Table 48 Number of Patent Applications, Schistosomiasis, by Assignee

Table 49 Number of Patent Applications, Schistosomiasis, by Year, 2010-2015

Table 50 Number of Patent Applications, Schistosomiasis, by Country

Table 51 Number of Patent Applications, Schistosomiasis, by Type

Table 52 Number of Patent Applications, Lymphatic Filariasis, by Assignee

Table 53 Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015

Table 54 Number of Patent Applications, Lymphatic Filariasis, by Country

Table 55 Number of Patent Applications, Lymphatic Filariasis, by Type

Table 56 Number of Patent Applications, Chagas Disease, by Assignee

Table 57 Number of Patent Applications, Chagas Disease, by Year, 2010-2015

Table 58 Number of Patent Applications, Chagas Disease, by Country

Table 59 Number of Patent Applications, Chagas Disease, by Type

Table 60 Number of Patent Applications, African Trypanosomiasis, by Assignee

Table 61 Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015

Table 62 Number of Patent Applications, African Trypanosomiasis, by Country

Table 63 Number of Patent Applications, African Trypanosomiasis, by Type

Table 64 Number of Patent Applications, Dengue, by Assignee

Table 65 Number of Patent Applications, Dengue, by Year, 2010-2015

Table 66 Number of Patent Applications, Dengue, by Country

Table 67 Number of Patent Applications, Dengue, by Type

Table 68 Number of Patent Applications, Ebola, by Assignee

Table 69 Number of Patent Applications, Ebola, by Year, 2010-2016

Table 70 Number of Patent Applications, Ebola, by Country

Table 71 Number of Patent Applications, Ebola, by Type

Table 72 Number of Patent Applications, Zika, by Assignee

Table 73 Number of Patent Applications, Zika, by Year, 2010-2016

Table 74 Number of Patent Applications, Zika, by Country

Table 75 Number of Patent Applications, Zika, by Type

Table 76 Abbreviations Used in Neglected Tropical Diseases Landscape

Table 77 Glossary of Terms Used in Neglected Tropical Diseases Landscape

Table 78 Report Sources

## List Of Figures

### LIST OF FIGURES

Summary Figure Global Market for Neglected Tropical Diseases, by Indication, 2015-2021

Figure 1 Global Number of Malaria Caused Deaths, 2011-2015

Figure 2 Global Number of Leishmaniasis Caused Deaths, 2011-2015

Figure 3 Global Leishmaniasis Years of Life Lost\*, 2011-2015

Figure 4 Global Number of Schistosomiasis Caused Deaths, 2011-2015

Figure 5 Global Schistosomiasis Years of Life Lost\*, 2011-2015

Figure 6 Number of Lymphatic Filariasis Endemic Countries, by Region

Figure 7 Number of Chagas Disease Caused Deaths, 2011-2015

Figure 8 Global Chagas Disease Years of Life Lost\*, 2011-2015

Figure 9 Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015

Figure 10 Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015

Figure 11 Global Number of African Trypanosomiasis Caused Deaths, 2011-2015

Figure 12 Global African Trypanosomiasis Years of Life Lost\*, 2011-2015

Figure 13 Average Annual Number of Dengue Fever Cases, 1960-2007

Figure 14 Number of Cases in American Region, 2012-2016

Figure 15 Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016

Figure 16 Global Number of Dengue Caused Deaths, 2011-2015

Figure 17 Global Dengue Caused Years of Life Lost\*, 2011-2015

Figure 18 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Cases, March 2014-February 2016

Figure 19 Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Deaths, March 2014-February 2016

Figure 20 Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-2016

Figure 21 Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021

Figure 22 Global Market for Malaria, by Region, 2014-2021

Figure 23 Global Market for Leishmaniasis, by Region, 2014-2021

Figure 24 Global Market for Schistosomiasis, by Region, 2014-2021

Figure 25 Global Market for Lymphatic Filariasis, by Region, 2014-2021

Figure 26 Global Market for Chagas Disease, by Geography, 2014-2021

Figure 27 Global Market for Dengue, by Region, 2014-2021

Figure 28 Global Market for Zika, by Region, 2014-2021

Figure 29 Clinical Trials in Malaria, by Intervention Type, January 2005-September

2016

Figure 30 Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016

Figure 31 Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016

Figure 32 Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016

Figure 33 Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016

Figure 34 Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September 2016

Figure 35 Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016

Figure 36 Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016

Figure 37 Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016

Figure 38 Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016

Figure 39 Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016

Figure 40 Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016

Figure 41 Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016

Figure 42 Patent Share for Treatment and Preventive Medicine in Malaria, by Year

Figure 43 Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US

Figure 44 Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year

Figure 45 Patent Share for Leishmaniasis, US and non-US

Figure 46 Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year

Figure 47 Patent Share for Schistosomiasis, U.S. and non-U.S.

Figure 48 Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year

Figure 49 Patent Share for Lymphatic Filariasis, U.S. and non-U.S.

Figure 50 Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year

Figure 51 Patent Share for Chagas Disease, by U.S. and non-U.S.

- Figure 52 Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year
- Figure 53 Patent Share for African Trypanosomiasis, US and non-US
- Figure 54 Patent Share for Treatment and Preventive Medicine in Dengue, by Year
- Figure 55 Patent Share for Dengue, U.S. and non-U.S.
- Figure 56 Patent Share for Treatment and Preventive Medicine in Ebola, by Year
- Figure 57 Patent Share for Ebola, U.S. and non-U.S.
- Figure 58 Patent Share for Treatment and Preventive Medicine in Zika, by Year
- Figure 59 Patent Share for Zika, U.S. and Non-U.S.
- Figure 60 DNDi Research Portfolio, by Phase of Development
- Figure 61 DNDi Research Portfolio, by Indication
- Figure 62 GlaxoSmithKline Research Portfolio, by Phase of Development
- Figure 63 GlaxoSmithKline Research Portfolio, by Indication
- Figure 64 MMV Research Portfolio, by Phase of Development
- Figure 65 MMV Research Portfolio, by Partner

## I would like to order

Product name: Global Markets for Neglected Tropical Disease Treatments

Product link: <https://marketpublishers.com/r/GA1BDA5B0A0EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA1BDA5B0A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970